Table 1.
HIV peptides | CMV peptides | P815/anti-CD3 | |
---|---|---|---|
PBMC Uninfected controls | |||
KIR3DL1++ HLA-Bw41 | 0/6 | 6/6 | |
KIR3DL1++ HLA-Bw6 | 0/3 | 3/3 | |
KIR3DS1++ | 1/1 | 1/1 | |
PBMC HIV-infected subjects | |||
KIR3DL1++ HLA-Bw4 | 0/10 | 0/6 | 4/4 |
KIR3DL1++ HLA-Bw6 | 0/6 | 1/8 | 2/2 |
KIR3DS1++ | 3/3 | 3/3 | 3/3 |
In vitro restimulation2 purified KIR3DL1++ | Flu peptide | ||
peptide + IL-2 + IL-7 | 0/4 | 2/2 | 1/1 |
Con A + IL-2 | 0/2 | 2/2 |
CD8+ KIR3DL1+ T cell responses against HIV or CMV peptides in PBMC from control and HIV-infected individuals with different genetic backgrounds and strong overall T cell responses against the corresponding peptides were assessed by surface and intracellular flow cytometry.
KIR3DL1+ cells purified from PBMC of KIR3DL1 homozygous individuals were restimulated with either specific peptides or mitogen (Con A) plus cytokines and the reactivity of expanded cells was tested against HIV, CMV or flu peptides by surface and intracellular flow cytometry.